We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

39 hedge funds and large institutions have $31.3M invested in Xenon Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 38 → 39 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.9% less ownership

Funds ownership: 56.17% → 55.27% (-0.9%)

22% less capital invested

Capital invested by funds: $40.3M → $31.3M (-$8.97M)

Holders
39
Holders Change
+1
Holders Change %
+2.63%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
9
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BI
BVF Inc
California
+$2.22M
2
SSA
Schonfeld Strategic Advisors
New York
+$489K
3
Morgan Stanley
Morgan Stanley
New York
+$317K
4
KPF
K2 Principal Fund
Ontario, Canada
+$186K
5
DCM
DAFNA Capital Management
California
+$149K

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$1.44M
2
ECM
Endurant Capital Management
California
-$1.36M
3
GTC
Ghost Tree Capital
New York
-$600K
4
SFM
Sphera Funds Management
Israel
-$391K
5
Renaissance Technologies
Renaissance Technologies
New York
-$339K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$61K +$75.4K +19,277 New
LWIC
27
Leith Wheeler Investment Counsel
British Columbia, Canada
$51K – – –
ARTA
28
A.R.T. Advisors
New York
$49K +$13K +3,329 +27%
DTL
29
Dynamic Technology Lab
Singapore
$41K +$50.8K +13,001 New
JP Morgan Chase
30
JP Morgan Chase
New York
$34K +$28.1K +7,200 +199%
Deutsche Bank
31
Deutsche Bank
Germany
$33K -$7.96K -2,037 -16%
IVM
32
InterWest Venture Management
California
$26K – – –
Bank of Montreal
33
Bank of Montreal
Ontario, Canada
$17K -$6.28K -1,607 -23%
TRCT
34
Tower Research Capital (TRC)
New York
$11K +$14.3K +3,655 New
Wells Fargo
35
Wells Fargo
California
$8K – – –
UBS Group
36
UBS Group
Switzerland
$8K +$9.89K +2,530 New
Citigroup
37
Citigroup
New York
$2K – – –
PCM
38
Prelude Capital Management
New York
$2K +$2.88K +738 New
FDCDDQ
39
Federation des caisses Desjardins du Quebec
Quebec, Canada
$126 -$39 -10 -20%
OM
40
Opaleye Management
Massachusetts
– -$1.44M -360,000 Closed
ECM
41
Endurant Capital Management
California
– -$1.36M -340,672 Closed
GTC
42
Ghost Tree Capital
New York
– -$600K -150,000 Closed
Geode Capital Management
43
Geode Capital Management
Massachusetts
– -$41K -10,386 Closed
1
2

XENE Hedge Fund Activity: Q2 2017 in Review

39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2017, worth a combined $31.3M — down 22% from $40.3M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 7 trimmed.

The largest buyer was BVF Inc, adding an estimated $2.22M. The largest seller was Opaleye Management, exiting entirely with an estimated $1.44M sold.

  • 39 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2017, up from 38 in Q1 2017.
  • Funds reported $31.3M of Xenon Pharmaceuticals stock for Q2 2017, down 22% quarter-over-quarter.
  • 6 funds opened new Xenon Pharmaceuticals positions in Q2 2017 and 5 closed out, a net change of +1 holder.
  • The largest Xenon Pharmaceuticals buyer in Q2 2017 was BVF Inc, an estimated $2.22M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2017 was Opaleye Management, an estimated $1.44M sold.

Based on aggregated 13F filings for Q2 2017.